Clinical Trial Update: Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial assessing osimertinib induction and maintenance for chemo-ineligible, unresectable stage III EGFR-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING